Stocks and Investing
Stocks and Investing
Wed, November 2, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mike Matson Maintained (ATRC) at Strong Buy with Decreased Target to $55 on, Nov 2nd, 2022
Mike Matson of Needham, Maintained "AtriCure, Inc." (ATRC) at Strong Buy with Decreased Target from $65 to $55 on, Nov 2nd, 2022.
Mike has made no other calls on ATRC in the last 4 months.
There are 3 other peers that have a rating on ATRC. Out of the 3 peers that are also analyzing ATRC, 0 agree with Mike's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Mike
- Marie Thibault of "BTIG" Maintained at Strong Buy with Decreased Target to $71 on, Monday, October 17th, 2022
- Matt O'Brien of "Piper Sandler" Maintained at Buy with Decreased Target to $55 on, Wednesday, August 3rd, 2022
- Rick Wise of "Stifel" Maintained at Strong Buy with Decreased Target to $50 on, Monday, July 18th, 2022
Contributing Sources